Fresenius Kabi AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fresenius Kabi AG
Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.
Fresenius Kabi has launched the first-ever generic version of Pfizer’s Foscavir in the US, with the product available immediately.
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Fresenius Kabi saw a sales and earnings slump in its North America business in the final quarter of last year, which dragged heavily on the firm’s full-year operations. Management have conceded that one of those factors, manufacturing issues at its Melrose Park facility, will blow into 2021, with no product approvals or launches anticipated from the site.
- Generic Drugs
- Infusion Therapy Equipment and Supplies